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A B S T R A C T
Pharmacological treatments in laboratory rodents remain a cornerstone of preclinical psychopharmacological
research and drug development. There are numerous ways in which acute or chronic pharmacological treat-
ments can be implemented, with each method having certain advantages and drawbacks. Here, we describe and
validate a novel treatment method in mice, which we refer to as the micropipette-guided drug administration
(MDA) procedure. This administration method is based on a sweetened condensed milk solution as a vehicle for
pharmacological substances, which motivates the animals to consume vehicle and/or drug solutions voluntarily
in the presence of the experimenter. In a proof-of-concept study, we show that the pharmacokinetic profiles of
the atypical antipsychotic drug, risperidone, were similar whether administered via the MDA procedure or via
the conventional oral gavage method. Unlike the latter, however, MDA did not induce the stress hormone,
corticosterone. Furthermore, we assessed the suitability and validity of the MDA method in a mouse model of
maternal immune activation, which is frequently used as a model of immune-mediated neurodevelopmental
disorders. Using this model, we found that chronic treatment (> 4 weeks, once per day) with risperidone via
MDA led to a dose-dependent mitigation of MIA-induced social interaction deficits and amphetamine hy-
persensitivity. Taken together, the MDA procedure described herein represents a novel pharmacological ad-
ministration method for per os treatments in mice that is easy to implement, cost effective, non-invasive, and less
stressful for the animals than conventional oral gavage methods.
1. Introduction
In-vivo animal models remain a cornerstone of preclinical research.
One main goal of modeling a disease is to achieve a more profound
understanding of its etiology and pathophysiology, which in turn may
identify possible targets for its treatment and/or optimize existing
treatment options. Pharmacological treatments in animal models are
also critical for ascertaining the predictive validity of a model, that is,
the extent to which pharmacological compounds that are known to
influence a clinical state in humans have a similar effect in the animal
model (Peleg-Raibstein et al., 2012).
Depending on the characteristics of the treatment (solubility of the
compound, pharmacokinetics, pharmacodynamics, and length of
treatment), experimenters can implement a variety of different
administration routes, all of which have their own advantages and
drawbacks. The latter can be substantial when considering chronic
administration regimes. For example, repeated restraint of the experi-
mental animal represents a chronic stressor to the animal, which in turn
can confound the results of the study (Vandenberg et al., 2014). Besides
inducing stress, chronic intraperitoneal (i.p.) or subcutaneous (s.c.)
injections can also lead to infections at the sites of injections, whereas
repeated oral gavages (o.g.) can cause perforation of the esophagus,
trachea or stomach (Arantes-Rodrigues et al., 2012; Burkholder et al.,
2012; Turner et al., 2011; Vandenberg et al., 2014). Thus, these ad-
ministration routes are suboptimal for chronic treatment regimens,
especially in small laboratory animals such as the mouse (Burkholder
et al., 2012; Turner et al., 2011).
By contrast, providing substances in food or drinking water is a non-
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stressful and non-invasive method that is commonly used for chronic
per os administration of substances (Turner et al., 2011). Because the
animals have constant access to the substance, however, the plasma
levels of the substance remain relatively constant throughout their ac-
tive phase but decline during the non-active phase (Delotterie et al.,
2009; Gao et al., 2009, 2005; Löscher and Schmidt, 1988; Meyer et al.,
2010). Therefore, one limitation of per os administration of substances
via food or drinking water is that it can lead to a plasmatic profile that
is different to that obtained in human oral administrations, where
substances are typically administered at discrete administration win-
dows and, depending on the substance, lead to a concentration peak in
the blood at specific time intervals (Kapur et al., 2003; Shaywitz et al.,
1982). Moreover, administration of a substance in the drinking water or
food requires constant titration of its concentration in order to ac-
commodate how much the animal weighs, eats, and drinks. Lastly,
when considering administration in the drinking water, this method
requires the drug to be soluble and stable in this vehicle, restricting this
method to only certain compounds.
The use of minipumps, which can be inserted into the peritoneal
cavity or subcutaneously, is a minimally invasive alternative to pro-
viding substances in drinking water or food for chronic treatments
(Gensler et al., 2012). Minipumps can deliver a preloaded solution
continuously at rates between 1 and 34 µL/min (Gensler et al., 2012),
thereby reducing the amount of daily stress for the animals. This
method guarantees constant levels of drug exposure, but it requires the
animal to undergo initial surgery for the minipump insertion and, in
many cases, necessitates post-surgical analgesic treatments (Gensler
et al., 2012; Theeuwes and Yum, 1976). Moreover, minipumps pose a
problem for their size and for poorly soluble compounds, and, similar to
per os administration of substances via food or drinking water, they can
lead to plasmatic profiles that are different to those obtained by oral
administrations at specific time intervals (Nau, 1986). Following a si-
milar principle to that of minipumps, slow-release pellets implanted
subcutaneously allow for chronic treatment with minimal experimenter
influence. While the animal is under general anesthesia, the pellets are
inserted subcutaneously in the scruff of the neck, where they slowly
dissolve, allowing the drug to enter the bloodstream over the course of
a set time frame with zero order kinetics (Bloomfield et al., 2018). The
duration of release varies from one to several weeks, depending on the
dimensions of the pellet and on the released compound. As a con-
sequence, in chronic studies longer than 21 days, pellets may have to be
replaced weekly, causing both stress to the animals and risks of infec-
tion at the insertion site with consequent dropout of experimental
subjects (Gasparini et al., 2016). Moreover, while some compounds
delivered through slow-releasing pellets reach a human-like steady-
state concentration (Bloomfield et al., 2018; Crowley et al., 2012; Kim
et al., 2018), others show a pattern of rapid high plasmatic con-
centration during the first days after implantation, which then steadily
decreases over the following days (Gasparini et al., 2016; McLane et al.,
2017). Lastly, both osmotic minipumps and slow-release pellets are
characterized by relatively high costs that render them less cost-effec-
tive as compared, for example, to administration via the drinking water
(Gasparini et al., 2016).
Taken together, all of the above-mentioned methods have inherent
limitations when adopted for chronic pharmacological treatments in
laboratory animals. Therefore, the present study was designed with the
aim to develop and validate a novel administration method that mini-
mizes these limitations while being applicable for chronic per os treat-
ments in mice. This method, which we hereby refer to as micropipette-
guided drug administration (MDA) procedure, is based on the use of a
palatable solution in the form of sweetened condensed milk mixed with
water. In this procedure, the animals are trained to ingest the palatable
drug (or vehicle) solution in a controlled manner in the presence of the
experimenter. The MDA technique allows repeated administration of
substances without the need for a full restraint or invasive techniques,
thus drastically minimizing the stressful impact on the experimental
animals and on the experimenter.
In order to validate the novel MDA method, we first compared the
pharmacokinetic profiles of the commonly used anti-psychotic drug,
risperidone (RIS), when administered via traditional oral gavage and
via MDA in mice. Risperidone is not readily soluble in water, rendering
it an ideal candidate for validating the suitability and efficiency of the
MDA method. Subsequently, we assessed the suitability and validity of
the MDA method in a mouse model of maternal immune activation
(MIA), which is frequently used as a model of immune-mediated neu-
rodevelopmental disorders in numerous species, including mice (Brown
and Derkits, 2010; Brown and Meyer, 2018; Estes and McAllister,
2016). This MIA model incorporates an established risk factor of var-
ious neurodevelopmental disorders (Brown and Derkits, 2010; Brown
and Meyer, 2018) and is based on maternal administration of the viral
mimetic poly(I:C) (=polyriboinosinic-polyribocytidilic acid). Prenatal
poly(I:C) exposure in laboratory mice and other species leads to mul-
tiple changes in brain functions and behavior with relevance to neu-
rodevelopmental and psychiatric disorders, such as autism spectrum
disorder and schizophrenia (Careaga et al., 2017; Harvey and Boksa,
2012a, 2012b; Meyer, 2014; Meyer et al., 2009). Adopting the MDA
method in the MIA model, we examined whether chronic RIS treatment
in adulthood could mitigate several poly(I:C)-induced behavioral defi-
cits, including impairments in social approach behavior, attenuation of
sensorimotor gating, and hyper-responsiveness to acute dopaminergic
stimulation (Meyer, 2014; Meyer et al., 2009).
2. Materials and methods
2.1. Animals
C57BL6/N mice (Charles River Laboratories, Sulzfeld, Germany)
were used throughout the study. They were caged 3–5 animals per cage
and sex in individually ventilated cages (IVCs) and kept under a re-
versed light–dark cycle (lights off: 09:00 AM–09.00 PM) as described
before (Mueller et al., 2018) and in the Supplemental Information. All
procedures described in the present study had been previously ap-
proved by the Cantonal Veterinarian’s Office of Zurich, and all efforts
were made to minimize the number of animals used and their suffering.
2.2. Micropipette-guided drug administration (MDA) procedure
The MDA procedure was based on the use of a palatable solution in
the form of sweetened condensed milk (MIGROS Kondensmilch™,
Migros, Zurich, Switzerland) mixed with regular tap water. The con-
densed milk contained unskimmed cow’s milk (59%), sugar (55 g per
100 g), and stabilizer E339. It was diluted with water, yielding to a 3:10
(condensed milk to water) ratio. The water-diluted condensed milk
solution was used as vehicle for risperidone (RIS) throughout the study.
RIS was first suspended in distilled water and 0.5% hydro-
xyethylcellulose, placed in an ultrasonic water bath, and sonicated for
20 min before being mixed with the vehicle (i.e., the water-diluted
condensed milk solution). The doses of RIS ranged between 0.4 and
0.8 mg/kg in the pharmacokinetic studies and included doses of 0.05
and 0.1 mg/kg in the MIA model (see below). The drug and vehicle
solutions were kept in constant agitation using magnetic stirrer (Stuart
UC152, Carl Roth, Karlsruhe, Germany) prior to administration via
MDA.
Vehicle and drug solutions were administered using a volume of
2 ml/kg and were provided with a conventional single channel p200
micropipette (Gilson Pipetteman, Thermo Fischer Scientific, Reinach,
Switzerland). Prior to the start of the actual drug or vehicle treatment,
all animals were first trained to obtain the condensed milk solution
from the micropipette on two consecutive days, with one training ses-
sion per day. On the first day of training, the mice were fully restrained
and exposed to the milk solution for the first time, as the pipette tip was
offered to the mouth until the mouse began to drink (Fig. 1A,
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Supplementary Video 1). On the second day of training, a looser re-
straint was used, such that the mice were restrained solely by the tail on
the metal grid of the food hopper (Fig. 1B, Supplementary Video 2).
Again, the pipette was continually positioned next to the mice’s mouth
until they drank. On the third day, by the time the treatment began (i.e.,
two days after the first training session), the mice no longer required
any restraint for them to voluntarily drink the solution (Fig. 1C,
Supplementary Video 3). For the assessment of the acute stress re-
sponses, weight gain, and therapeutic effects of RIS in the MIA model
(see below), two different experimenters were assigned to conduct the
oral gavage and/or MDA procedures in order to counterbalance po-
tential experimenter bias. Hence, half the animals in each treatment
group was treated by one experimenter, and the other half was treated
by a different experimenter.
2.3. Pharmacokinetic studies
A proof-of-concept study was conducted to assess the pharmacoki-
netics of RIS administration using the MDA procedure. To this aim, RIS
was administered either using MDA as described above, or via the
conventional oral gavage route. When administering RIS via oral ga-
vage, the drug was suspended in distilled water and 0.5% hydro-
xyethylcellulose, placed in an ultrasonic water bath, sonicated for
20 min, and kept under agitation until treatment (the time between
sonication and treatment did not exceed 10 min). Two doses of RIS
were chosen (0.4 and 0.8 mg/kg) based on previous uses of RIS in
mouse models (Kohlhaas et al., 2012), and administered as described in
the Supplementary Information. Blood samples were taken via tail vein
sampling after 30, 60, and 90 min after RIS administration, and cen-
trifuged at 4 °C for 10 min to separate the plasma, which was stored at
−70 °C. Plasma concentrations of RIS were determined using standard
tandem liquid chromatography mass spectrometry (LC-MS/MS). For the
pharmacokinetic studies, adult (10–12-week-old) male C57BL6/N mice
(Charles River Laboratories, Sulzfeld, Germany) were used. They were
kept as described above.
2.4. Assessment of acute stress response
A first experiment was designed to assess whether the MDA proce-
dure might differ from the conventional oral gavage method in terms of
inducing stress. To this end, we measured plasma corticosterone
(CORT) levels 30 min after MDA or oral gavage in adult (10–12-week-
old) male C57BL6/N mice (Charles River Laboratories, Sulzfeld,
Germany). Two groups of animals were habituated to either treatment
method for 6 days, and one group of animals was kept undisturbed and
used as baseline. CORT was then measured after treatment on the 7th
day as described before (Mueller et al., 2018).
In a second experiment, we measured CORT levels during the
learning phase of the MDA procedure, that is, 30 min after MDA ad-
ministration on day 1 (which requires a full restraint; see
Supplementary Video 1), day 2 (which only requires a tail restraint on
the food hopper; see Supplementary Video 2) and day 3 (when the
animals freely drink from the micropipette without any restraint being
used; see Supplementary Video 3). These three groups were compared
to animals that were left undisturbed (baseline measures; taken on each
day) and a group of animals subjected to oral gavage for the first time
(corresponding to day 1 of the MDA procedure). In addition, we mea-
sured the time it took the animals to drink the required volume of so-
lution on all of the three days.
For all CORT measures, trunk blood was collected after decapita-
tion. After collection, the blood samples were spun at 4 °C for 10 min to
separate the plasma, and plasma CORT was analyzed with the DetectX®
Corticosterone Enzyme Immunoassay kit (Arbor Assays, Ann Arbor,
USA) according to the manufacturer’s instructions.
2.5. Assessment of weight gain during chronic administration with MDA
We also compared the weight gain of male and female C57BL6/N
mice (Charles River Laboratories, Sulzfeld, Germany) chronically ex-
posed to the MDA procedure, relative to mice that were left un-
disturbed, starting from postnatal day (PND) 21 until they reached PND
90. These measurements served to assess whether chronic daily con-
sumption of a limited amount of condensed milk, which is an inherent
part of the MDA procedure, might affect the growth and weight of the
treated animals.
2.6. Maternal immune activation model
Female and male C57BL6/N breeder mice were exposed to a timed-
mating procedure as described previously (Meyer et al., 2005; Mueller
et al., 2018) and in the Supplementary Information.
Pregnant dams were subjected to either a single injection of poly
(I:C) at a dose of 2.5 mg/kg (potassium salt; Sigma–Aldrich, Buchs, St
Gallen, Switzerland, lot #117M4005V) or vehicle on gestation day 12
as described in detail in the Supplementary Information (Mueller et al.,
2019, 2018). A total of 28 litters (13 poly(I:C) and 15 vehicle control
litters) were prepared in order to minimize possible litter effects
(Supplementary Information). The housing and experimental allocation
of the poly(I:C)-exposed or control offspring are described in the
Supplementary Information. A reporting guideline checklist for the MIA
model (Kentner et al., 2019) is also provided in the Supplementary
Table S1.
RIS or corresponding vehicle treatment via MDA started when poly
Fig. 1. Phases of the micropipette-guided drug administration (MDA) method
in C57BL6/N mice. (A) First day of MDA training: Mice are fully restrained and
exposed to the sweetened condensed milk solution for the first time via a
conventional micropipette (see also Supplementary Video 1). (B) Second day of
MDA training: Mice are restrained solely by the tail and exposed to the swee-
tened condensed milk solution via a micropipette (see also Supplementary
Video 2). (C) Third day of MDA training (when the actual treatment would
start): Mice are no longer restrained and drink the sweetened condensed milk
solution voluntarily from the micropipette (see also Supplementary Video 3).
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(I:C)-exposed or control offspring reached postnatal day (PND) 70
(Supplementary Fig. S1). Based on initial RIS dose response studies
(Supplementary Fig. S2) and previous studies conducted in the MIA and
neonatal ventral hippocampal lesion (NVHL) models (Piontkewitz
et al., 2011, 2012; Richtand et al., 2006), RIS was given at a dose of
0.05 or 0.1 mg/kg/day in order to minimize possible confounds arising
from sedation, and to assess whether the preventive effects of RIS ad-
ministered at these doses (Piontkewitz et al., 2012, 2011; Richtand
et al., 2006) may be extended to therapeutic effects when given
chronically in adulthood. Chronic administration of RIS or vehicle via
MDA followed procedures as described above and lasted for a total of
6 weeks. Behavioral testing (see below) was conducted during the last
three weeks of the treatment, with animals receiving either RIS or ve-
hicle 30 min before testing. Behavioral testing involved the assessment
of (1) social approach behavior in a modified Y-maze, (2) sensorimotor
gating in the form of prepulse inhibition (PPI) of the acoustic startle
reflex, and (3) amphetamine-induced hyperlocomotion in the open
field. These tests were selected because they capture core behavioral
deficits induced by poly(I:C)-based MIA in mice (Luan et al., 2018;
Notter et al., 2018; Weber-Stadlbauer et al., 2017). The testing appa-
ratuses and procedures are described in the Supplementary
Information. Both male and female animals were included to examine
possible sex-dependent effects.
2.7. Statistical analysis
All data were analyzed using parametric analysis of variance
(ANOVA) as described in the Supplementary Information. Whenever
appropriate, ANOVAs were followed by Tukey’s post-hoc test to control
for multiple comparisons. All statistical analyses were performed using
SPSS Statistics (version 22.0, IBM, Armonk, NY, USA) and Prism (ver-
sion 7.0; GraphPad Software, La Jolla, CA, USA). Statistical significance
was set at p < 0.05.
3. Results
3.1. Effects of the treatment method on the stress response, weight gain, and
pharmacokinetic profile of risperidone
The animals generally took<5 s to consume the condensed milk
solution from the micropipette in the MDA procure (Fig. 2A). The
consumption time was relatively constant (ranging between 1 and 5 s)
across days when the animals were considered as a group. When con-
sidering individual animals, there was a non-significant day-to-day
variation in terms of the time required to consume the condensed milk
solution from the micropipette (Fig. 2A).
To examine whether the MDA procedure differs from the traditional
method of oral gavage in terms of inducing stress, we measured plasma
CORT levels 30 min after MDA or oral gavage. An additional non-
treated group of mice was included as a negative control group. As
shown in Fig. 2B, the plasma CORT levels in MDA-treated and non-
treated mice did not significantly differ on day 1 of the MDA procure,
whereas mice subjected to oral gavage for the first time showed sig-
nificantly higher CORT levels compared to MDA-treated (p < 0.01)
and non-treated (p < 0.001) mice (main group effect ANIOVA:
F(2,17) = 11.99, p < 0.001). To explore whether these differences
persist under chronic treatment conditions, we assessed the effects of
habituation to the different treatment regimens. As shown in Fig. 2C,
the treatment method significantly (F(2,24) = 11.97, p < 0.001) in-
fluenced plasma CORT levels even after 6 days of habituation to either
oral gavage or MDA, with mice treated via oral gavage for 6 days
showing a two-fold increase in plasma CORT levels compared to mice
undergoing the MDA procedure for 6 days (p < 0.01), or compared to
non-treated mice (p < 0.001). Importantly, plasma CORT levels did
not differ between non-treated mice and mice receiving the condensed
milk solution via MDA for 6 days (Fig. 2C). We also assessed plasma
CORT levels during the learning phase of the MDA procedure, and
observed that plasma CORT levels did not differ between MDA-treated
and non-treated mice during this time. Indeed, CORT levels in MDA-
treated mice did not significantly differ from non-treated mice on days
2 and 3 of MDA training (Supplementary Fig. S3).
Compared with non-treated animals, chronic daily intake of the
condensed milk solution did not influence body weight gain from PND
21 to 90 in mice assigned to the MDA procedure (Fig. 2D). Using RIS as
a proof-of-concept drug, there was also no evidence for the possibility
that the pharmacokinetic profile differs between MDA and oral gavage
procedures. Indeed, at either dose of RIS (0.4 or 0.8 mg/kg), the plasma
exposure (nM) of RIS did not differ between the MDA and oral gavage
methods (Supplementary Fig. S4). For both doses and treatment
methods examined, plasma exposure of RIS was maximal at the 30-
minutes post-treatment sampling interval and subsided afterwards
(Supplementary Fig. S4), demonstrating similar pharmacokinetic pro-
files after MDA and oral gavage.
3.2. Effects of chronic risperidone given via MDA on social deficits in the
MIA model
We used the poly(I:C)-based MIA model in mice to validate the
utility and effectiveness of the MDA procedure in preclinical animal
models of neurodevelopmental disorders. To this aim, we treated adult
offspring of poly(I:C)-treated or control mothers chronically (6 weeks)
with RIS (0.05 or 0.1 mg/kg/day) or corresponding vehicle via MDA
and subjected them to behavioral testing.
First, we assessed the effects of the pharmacological treatment on
social approach behavior using a modified version of the three-chamber
social interaction test (Notter et al., 2018; Weber-Stadlbauer et al.,
2017). Social approach behavior was significantly influenced by both
prenatal treatment and drug treatment, as indicated by the significant
two-way interaction in the analysis of the social preference index
(F(2,81) = 11.18, p < 0.01). Vehicle-treated MIA offspring showed a
significantly (p < 0.01) reduced social preference index compared to
vehicle-treated control offspring (Fig. 3A). The MIA-induced social
deficit was also evident in the analysis of the absolute exploration time,
which yielded a significant three-way interaction between prenatal
treatment, drug treatment, and object (F(2,81) = 5.87, p < 0.01). In-
deed, whereas vehicle-treated control offspring showed a clear pre-
ference for the unfamiliar live mouse relative to the inanimate dummy
object (p < 0.01), vehicle-treated MIA offspring did not (Fig. 3B).
The analysis of the social preference index further showed that the
MIA-induced social deficit was normalized by chronic treatment with
the lower (0.05 mg/kg/day) dose of RIS (Fig. 3A). This effect stemmed
from a significant reduction (p < 0.01) in the relative time MIA off-
spring spent with the dummy object after chronic treatment with RIS at
a dose of 0.05 mg/kg/day (Fig. 3B). By contrast, chronic treatment with
the higher (0.1 mg/kg/day) dose of RIS failed to normalize the MIA-
induced social deficit but, instead, significantly (p < 0.01) reduced the
social preference index in control offspring (Fig. 3A). The latter effect
was accounted for by the drug’s effect on the exploration time with the
unfamiliar live mouse, which markedly decreased after chronic treat-
ment with RIS at a dose of 0.1 mg/kg/day, particularly in offspring of
control mothers (p < 0.01, Fig. 3B).
The between-subject factor of sex did not significantly interact with
prenatal treatment and/or drug treatment, neither in the analysis of the
social preference index (prenatal treatment × sex: F(1,81) = 0.01,
p = 0.97; prenatal treatment × drug treatment × sex: F(2,81) = 0.66,
p = 0.52), nor in the analysis of the absolute exploration time (prenatal
treatment × sex × object: F(1,81) = 0.01, p = 0.98; prenatal treat-
ment × drug treatment × sex × object: F(2,81) = 0.45, p = 0.65).
Hence, the MIA-induced social deficit and its normalization by the
lower dose of RIS were independent of the offspring’s sex.
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3.3. Effects of chronic risperidone given via MDA on sensorimotor gating
deficits in the MIA model
Next, we examined the effects of chronic RIS treatment given via
MDA on sensorimotor gating deficits in the MIA mouse model (Meyer,
2014; Mueller et al., 2018; Richetto et al., 2013). Sensorimotor gating
was measured using the test of prepulse inhibition (PPI) of the acoustic
startle reflex (Peleg-Raibstein et al., 2012). In all groups, the % PPI
scores increased with increasing prepulse intensities, as supported by
the significant main effect of prepulse level (F(2,162) = 1039.38,
p < 0.001) and its interaction with pulse level (F(4,324) = 11.46,
p < 0.001). MIA led to a significant overall reduction in % PPI, as
supported by the significant main effect of prenatal treatment
(F(1,81) = 4.71, p < 0.05; Fig. 4A). RIS (0.05 or 0.1 mg/kg/day) did
not improve PPI in MIA-exposed offspring, nor did it significantly affect
PPI in control offspring (Fig. 4A). Furthermore, there were no sig-
nificant interactions involving the between-subject factor of sex in the
analysis of % PPI (prenatal treatment × sex: F(1,81) = 0.28, p = 0.60;
prenatal treatment × drug treatment × sex: F(2,81) = 0.02, p = 0.98),
indicating that the MIA-induced PPI deficit and lack of normalization
by RIS were independent of the sex of the offspring.
There were also no significant main effects or interactions involving
the between-subject factors of prenatal treatment and/or drug treat-
ment in the analysis of reactivity to pulse-alone or prepulse-alone trials.
In all groups and in both sexes, the reactivity to pulse-alone and pre-
pulse-alone trials increased with increasing pulse (Fig. 4B) and prepulse
(Fig. 4C) intensities, respectively (main effect of pulse:
F(2,162) = 184.94, p < 0.001; main effect of prepulse: F(2,162) = 17.04,
p < 0.001).
3.4. Effects of chronic risperidone given via MDA on amphetamine
hypersensitivity in the MIA model
We also examined whether chronic RIS treatment given via MDA
could normalize the hypersensitivity to acute dopaminergic stimulation
by systemic AMPH, which has previously been found in poly(I:C)-based
MIA models (Luan et al., 2018; Meyer et al., 2008; Vuillermot et al.,
2010; Zuckerman et al., 2003). Neither MIA nor chronic treatment with
RIS given at 0.05 or 0.1 mg/kg/day affected basal locomotor activity
during the initial habituation or subsequent vehicle administration
Fig. 2. Effects of the micropipette-guided drug administration (MDA) method on measures of growth and stress. (A) Time needed to consume the sweetened
condensed milk solution in the MDA method. The graph shows the performance of individual animals during the three initial days of MDA training. N = 10 male
C57BL6/N mice (10–12 weeks of age). (B) Plasma CORT levels 30 min after MDA in male C57BL6/N mice on the first day of MDA training. Non-treated (NT) mice
were used as negative control groups, whereas mice treated with conventional oral gavage (OG) were used as a positive control group. **p < 0.01 and
***p < 0.001, based on post-hoc tests following ANOVA. N= 6–8 mice per group. (C) Plasma corticosterone (CORT) levels 30 min after MDA or conventional OG in
male C57BL6/N mice after habituation to either treatment method for 6 days. A non-treated (NT) control group of mice that was left undisturbed was used for
baseline CORT measures. **p < 0.01 and ***p < 0.001, based on post-hoc tests following ANOVA. N = 9 mice per group. Dots represent individual animals, and
error bars represent S.E.M. (D) Body weights in male and female mice (C57BL6/N) assigned to daily MDA treatment starting from postnatal day (PND) 21 to PND 90,
relative to mice that were left undisturbed and non-treated (NT) during this period. N = 13 per sex and treatment condition.
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phase of the AMPH sensitivity test (Fig. 5A). As expected, systemic
AMPH administration led to an increase in the animals’ locomotor ac-
tivity, which generally peaked between 20 and 40 min after AMPH
treatment (main effect of bins: F(17,1377) = 68.16, p < 0.001). The
AMPH-induced hyperactivity response was significantly potentiated in
MIA offspring relative to control offspring (Fig. 5A), as supported by the
main effect of prenatal treatment (F(1,81) = 4.03, p < 0.05). Both doses
of RIS significantly reduced AMPH-induced hyperactivity both in MIA-
Fig. 3. Effects of chronic risperidone treatment on social deficits in the maternal immune activation model. Poly(I:C)-exposed (POL) and control (CON) offspring
were subjected to chronic treatment with risperidone at a dose of 0.05 mg/kg/day (R0.05) or 0.10 mg/kg/day (R0.10), or to corresponding vehicle (Veh) treatment,
prior to the social interaction test. (A) Social preference index: Values > 0 represent a preference towards an unfamiliar mouse, whereas values < 0 represent a
preference towards an inanimate dummy object. *p < 0.05 and **p < 0.01, based on post-hoc tests following ANOVA. N = 14–16 per group. Dots represent
individual animals, and error bars represent S.E.M. (B) Absolute exploration times of unfamiliar mouse and inanimate dummy object. §§p < 0.01, reflecting the
significant difference between mouse and dummy exploration times in Veh- and R0.05-treated CON offspring; +p < 0.05, reflecting the significant difference
between mouse and dummy exploration times in R0.05-treated POL offspring. N = 14–16 per group; values are means ± S.E.M.
Fig. 4. Effects of chronic risperidone treatment on prepulse inhibition deficits in the maternal immune activation model. Poly(I:C)-exposed (POL) and control (CON)
offspring were subjected to chronic treatment with risperidone at a dose of 0.05 mg/kg/day (R0.05) or 0.10 mg/kg/day (R0.10), or to corresponding vehicle (Veh)
treatment, prior to the prepulse inhibition test. (A) The line plots show % prepulse inhibition as a function of prepulse intensity (+6, +12 and + 18 dBA above
background of 65 dBA) for each of the three pulse conditions (P‐100, P‐110 and P‐120, which correspond to pulse intensities of 100, 110 and 120 dBA). The bar plots
depict the mean % prepulse inhibition across the three prepulse intensities in each pulse condition. *p < 0.05, reflecting the significant main effect of prenatal
treatment based on ANOVA. (B) Pulse-induced reactivity (in arbitrary units, AU) as a function of pulse intensity (P‐100, P‐110 and P‐120, which correspond to pulse
intensities of 100, 110 and 120 dBA). (C) Prepulse-induced reactivity (in arbitrary units, AU) as a function of prepulse intensity (+6, +12 and + 18 dBA above
background of 65 dBA). For all data, N = 14–16 per group. Dots in bar plots represent individual animals; all line plots represent means ± S.E.M.
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exposed offspring and in control offspring (Fig. 5A), leading to a sig-
nificant main effect of drug treatment (F(2,81) = 5.05, p < 0.01). The
interaction between prenatal treatment and drug treatment failed to
attain statistical significance (F(2,81) = 1.63, p = 0.20), and so did the
three-way interaction between prenatal treatment, drug treatment, and
bins (F(34,1377) = 0.24, p = 0.98). Likewise, the between-subject factor
of sex did not significantly interact with prenatal treatment (prenatal
treatment × sex: F(1,81) = 2.08, p = 0.15), drug treatment (drug
treatment × sex: F(2,81) = 0.07, p = 0.93; prenatal treatment × drug
treatment × sex: F(2,81) = 1.06, p = 0.35) and/or bins (prenatal
treatment × sex × bins: F(17,1377) = 1.32, p = 0.11; drug treat-
ment × sex × bins: F(34,1377) = 0.81, p = 0.76), showing that the
effects of MIA and RIS were independent of the offspring’s sex.
4. Discussion
Our study validated a newly developed pharmacological adminis-
tration method for per os treatments in mice. The MDA method de-
scribed herein makes use of a sweetened condensed milk solution as
vehicle for pharmacological substances. Condensed milk is highly pa-
latable to rodents and can mask the possibly aversive taste of phar-
macological compounds and solubilizing agents, motivating the ani-
mals to learn to consume vehicle and/or drug solutions voluntarily.
Indeed, because of its palatable nature, mice quickly (< 3 days) learned
to voluntarily drink this solution from conventional micropipettes in
the presence of the experimenter. Thus, the MDA technique allows
administration of substances without the need for a full restraint or
invasive techniques, thereby minimizing the stressful impact on the
experimental animals. The latter notion is supported by our findings
showing that mice undergoing the MDA procedure did not differ from
non-treated animals in terms of plasma levels of the stress hormone,
CORT. By contrast, mice treated via oral gavage showed a two-fold
increase in plasma CORT levels compared to mice undergoing the MDA
procedure or non-treated animals. These results are consistent with
previous findings showing significant increases in stress responses after
substance administration via oral gavage in mice (Gonzales et al.,
2014). Notably, the gavage-induced stress response was still present
30 min post-treatment and could potentially affect neurobehavioral
readouts through affecting locomotor activity and anxiety-like behavior
(Boyle et al., 2006; Tronche et al., 1999). Conversely, since MDA did
not lead to a significant increase in CORT, this method may allow for a
less confounded examination of drug effects on neurobehavioral read-
outs.
Importantly, the MDA procedure is also highly suitable for chronic
pharmacological treatments requiring repeated per os administration of
substances. During 6-week (starting from adulthood) or 11-week
(starting from weaning) treatment periods, in which mice underwent
the MDA procedure daily, we did not observe any drop out of experi-
mental subjects due to possible saturation to the condensed milk solu-
tion and/or injuries acquired during treatment, the latter of which is a
typical characteristic of chronic treatment by oral gavage (Arantes-
Rodrigues et al., 2012; Burkholder et al., 2012; Turner et al., 2011;
Vandenberg et al., 2014). Our results also indicate that the MDA pro-
cedure is suitable for preventive treatments in young animals. Indeed,
in our 11-week exposure experiment, juvenile mice at PND 21 were
already very compliant to the method and showed no differences in
consuming the condensed milk solution when compared to older ani-
mals. This is particularly relevant to the field of neurodevelopmental
research, where preventive interventions are of great interest. More-
over, the MDA technique requires no invasive procedures, unlike
methods that call for the implantation of release devices, such as
minipumps (Gensler et al., 2012; Theeuwes and Yum, 1976), and it
Fig. 5. Effects of chronic risperidone treatment on amphetamine hypersensitivity in the maternal immune activation model. Poly(I:C)-exposed (POL) and control
(CON) offspring were subjected to chronic treatment with risperidone at a dose of 0.05 mg/kg/day (R0.05) or 0.10 mg/kg/day (R0.10), or to corresponding vehicle
(Veh) treatment, prior to the amphetamine-induced hyperlocomotion test. (A) The line plots show the distance moved (cm) per 5-minute bins during the initial
acclimatization phase and subsequent saline (SAL) and amphetamine (AMPH) treatment phases. (B) Mean distance moved during the AMPH treatment phase.
*p < 0.05, reflecting the significant main effect of prenatal treatment based on ANOVA; ++p < 0.01, reflecting the significant main effect of risperidone treatment
based on ANOVA. (C) Computer-generated travel paths of representative Veh-treated CON and POL offspring and POL offspring treated with risperidone at a dose of
0.05 (R0.05) or 0.10 (R0.10) mg/kg/day. The paths illustrate the total distance traveled during the AMPH phase. For all data, N = 14–16 per group. Dots in bar plots
represent individual animals; all line plots represent means ± S.E.M.
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allows the experimenter to easily tailor the daily administration vo-
lumes to each mouse. Another advantage of the MDA procedure is that
it is very quick, both in terms of the initial learning phase and the drug/
vehicle consummation phase. With regards to the latter, we found that
animals only took between 1 and 5 s to consume the condensed milk
solution (with or without RIS) when offered from the micropipette.
While administering substances via home-cage food or drinking
water represents, similarly to the MDA method, a non-invasive way for
chronic per os treatments, it can lead to plasmatic profiles that are
different to those obtained in human oral treatment regimens. In human
settings, substances are typically administered at discrete administra-
tion windows and, depending on the substance, lead to a concentration
peak in the blood at specific time intervals (Kapur et al., 2003; Shaywitz
et al., 1982). Moreover, administration of substances in the home cage
drinking water or food is associated with several other drawbacks,
which in turn are avoidable with the MDA technique. First, compounds
that are insoluble in water have to be pre-dissolved in solubilizing
agents such as dimethyl sulfoxide (DMSO) and/or acetic acid, which
could produce an aversive reaction when given chronically (Colucci
et al., 2008; Turner et al., 2011). Second, these procedures require
regular (often daily) measurements of water or food intake to readjust
the drug concentrations given via home cage food or water. Third, to
accurately measure water or food intake, the animals are often single-
housed for the duration of the treatment, which represents, per se, a
strong stressor, especially when considering chronic manipulations
(Arakawa, 2018). Taken together, while our findings do not invalidate
the usefulness of experimental procedures in which RIS is given via
home cage drinking water (Parikh et al., 2004; Richtand et al., 2011;
Rosengarten and Quartermain, 2002) or food, we deem the MDA pro-
cedure a precise and time-effective alternative to this approach.
Here, we also provided an initial pharmakokinetic validation of the
the MDA procedure. Consistent with pharmacokinetic studies in human
subjects (Heykants et al., 1994), we found that RIS was rapidly ab-
sorbed following per os administration via MDA, with peak plasma le-
vels occurring 30 min after administration. Moreover, our pharmaco-
kinetic analyses showed that there were no differences in the plasma
levels of RIS when administered via MDA or oral gavage. Hence, while
having the advantage of minimizing stress responses in experimental
animals, the MDA procedure leads to desired plasmatic drug profiles
similar to conventional oral administration techniques.
Our study further assessed the preclinical validity and utility of the
MDA method in a poly(I:C)-based mouse model of MIA, which is fre-
quently used as a model of immune-mediated neurodevelopmental
disorders in numerous species, including mice (Brown and Derkits,
2010; Brown and Meyer, 2018; Estes and McAllister, 2016; Kentner
et al., 2019). Consistent with numerous previous studies in mice (re-
viewed in (Brown and Derkits, 2010; Brown and Meyer, 2018; Estes and
McAllister, 2016; Kentner et al., 2019), we found that prenatal exposure
to poly(I:C) impaired social approach behavior, attenuated PPI of the
acoustic startle reflex, and potentiated AMPH-induced hyperlocomo-
tion. These effects emerged similarly in male and female offspring, as
the inclusion of the between-subjects factor of sex did not reveal any
sex-dependent effects of MIA. Chronic RIS treatment via MDA mitigated
the MIA-induced abnormalities in sociability and AMPH responsive-
ness, further supporting the validity of the MDA method in preclinical
psychopharmacological research. To the best of our knowledge, our
study is the first to show therapeutic effects of RIS treatment on MIA-
induced behavioral dysfunctions when the drug is administered in
adulthood. A number of previous studies using MIA models investigated
the preventive potential of RIS and other antipsychotic drugs when
administered during asymptomatic stages, that is, before the onset of
full-blown behavioral dysfunctions in adulthood (Meyer et al., 2010;
Piontkewitz et al., 2011, Piontkewitz et al., 2009). While these studies
provided evidence for preventive effects of RIS (and other antipsychotic
drugs) in MIA models, the present data support the effectiveness of
chronic RIS to mitigate abnormalities in social interaction and AMPH
hypersensitivity.
Contrary to these effects, however, chronic RIS treatment in adult-
hood was ineffective in normalizing the MIA-induced deficits in PPI of
the acoustic startle reflex. Previous work in rats (Romero et al., 2007)
and mice (Vuillermot et al., 2010) suggests that MIA-induced PPI de-
ficiency can be mitigated efficiently by pharmacological inhibitors of
dopamine receptors, especially those targeting the D2 subtype. Con-
trary to the agents used in these previous studies, RIS has a more
complex pharmacological profile and is characterized by low D2 re-
ceptor affinity (Leysen et al., 1994; Schatzberg and Nemeroff, 2009).
Specifically, serotonin 5HT2A and dopamine D2 receptor occupancy
predominate at lower and higher doses of RIS, respectively, and the
difference between the occupancy of 5HT2A and D2 receptors produced
by RIS becomes smaller as the dose is increased (Arnt and Skarsfeldt,
1998; Janssen et al., 1988; Schotte et al., 1996). The low doses of RIS
implemented in the present study exert a predominantly 5HT2A re-
ceptor antagonistic action, with weak dopamine D2 receptor antag-
onism (Megens et al., 1994), suggesting that this receptor binding
profile is sufficient to rescue social behavior abnormalities and am-
phetamine hypersensitivity induced by MIA. Consequently, higher RIS
doses would be needed for predominant D2 receptor occupancy to
occur, suggesting furthermore that a normalization of MIA-induced PPI
deficits may require treatments with higher RIS doses than those used
in the present study (0.05 and 0.1 mg/kg/day). Our initial dose re-
sponse studies showed, however, that doses of RIS above 0.1 mg/kg led
to sedative effects, which in turn could have confounded the inter-
pretation of some of our behavioral readouts. Therefore, the present
study focused on RIS doses that were lower or equal than 0.1 mg/kg/
day. The choice of the present RIS dosing regimen was further based on
previous preclinical studies assessing the preventive effects of RIS in the
MIA and NVHL models (Piontkewitz et al., 2012, 2011; Richtand et al.,
2006), which revealed a prevention of social interaction deficits and
AMPH hypersensitivity at low doses of RIS comparable to those used
here. Future studies are required to explore whether RIS at higher doses
is effective in mitigating MIA-induced PPI deficits or not, and if chronic
exposure to the drug could somehow lead to a tolerance to its sedative
effects, allowing for higher doses to be administered in settings where
the behavioral testing is carried out at peak plasma levels of the drug.
We further acknowledge that our study is somewhat limited when
considering the portfolio of behavioral tests we chose to include. For
example, our study did not investigate the possible impact of chronic
exposure to the condensed milk solution on tests that are based on taste
and food consumption, as for example the sucrose preference test or the
novelty suppressed feeding test. However, given that even chronic ad-
ministration of condensed milk solution did not affect the weight gain
of the exposed animals, we deem it unlikely that the MDA procedure
affects their general food intake and thus their motivation to eat or
drink rewarding substances in a testing context. Moreover, we did not
assess the effects of RIS on other important behavioral abnormalities
that characterize the MIA model, such as cognitive deficits alterations
in learned fear and affective behaviors. A comprehensive behavioral
screening would go beyond the main scope of our study, which was to
perform a proof-of-concept validation regarding the validity of the MDA
procedure as applied to chronic drug treatments in an established
model of neurodevelopmental disorders, which is arguably very sensi-
tive to invasive chronic manipulations. It is also important to emphasize
that the observed similarities between the pharmacokinetics profiles of
RIS when given in condensed milk via MDA or when administered using
other solvents and oral application methods may not necessarily be
generalizable to other pharmaceuticals, as they might interact differ-
ently with the condensed milk. Furthermore, the condensed milk so-
lution might affect the solubility of certain compounds, rendering the
use of such vehicle problematic. While this can be avoided by pre-dis-
solving the compound in the most appropriate vehicle and then mixing
it with condensed milk, an extension to other compounds and model
systems would further corroborate the suitability and validity of the
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MDA procedure in preclinical pharmacological research. Given the
palatable nature of the method, and the higher predisposition of rats to
interact with the experimenter and learn non-aversive tasks, we also
deem the MDA technique a suitable drug treatment method in pre-
clinical rat models.
In conclusion, our study presents a novel pharmacological treatment
method that can be used efficiently for per os treatments in small la-
boratory rodents such as mice. The MDA procedure is not only non-
invasive and less stressful for the animals than conventional oral ga-
vages, but also it is easy to implement and cost-effective. This method
appears particularly suitable when oral treatments are to be given
chronically, as it is without risks of introducing gavage-induced injuries
to the digestive tract or infections at the sites of repeated i.p. or s.c.
injections. Because the MDA procedure allows the experimenter to
adjust the administration volume according to the animal’s body
weight, it can be efficiently applied to settings where body weight
changes occur as a function of age and/or experimental manipulations.
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